| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensifying and pushing technolog...
Leerink Partners analyst Faisal Khurshid downgrades AbCellera Biologics (NASDAQ:ABCL) from Outperform to Market Perform and ...
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of...
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading...
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices w...
AbCellera's stock rose 7.72% in after-hours trading following an 18.49% gain during regular trading, with a strong performa...